Developer docs
API playgroundTry for free, no card

Search company profiles

Moon Surgical

Full company profile

uuid0000dqq

Namestring
Moon Surgical
Legal namestring
Moon Surgical
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Moon Surgical is a Paris-based surgical robotics company, founded in 2020 (originally as MastOR), that develops the Maestro System, a collaborative and adaptive robotic platform designed to assist surgeons during laparoscopic and minimally invasive procedures. The system features gravity-defying robotic arms that operate without clutching or foot pedals, and is engineered to be compatible with standard off-the-shelf 5mm and 10mm instruments from any manufacturer - a deliberate departure from the proprietary-consumable model used by incumbent surgical robotics platforms. The Maestro platform is FDA-cleared (initial 510(k) in December 2022, commercial version in June 2024) and CE-marked (April 2023), and is sold to hospitals, surgical centers, and ambulatory surgery centers performing general, bariatric, gynecologic, and urologic procedures.

The platform's differentiation rests on integrated AI capabilities built on NVIDIA Holoscan technology. ScoPilot, FDA-cleared in March 2025, is the first AI application to run intraoperatively on any commercially available surgical robotic platform, providing automatic laparoscope positioning that frees the surgeon's hands. The platform evolved in June 2026 with Maestro Software Version 2.7 into a multi-model Physical AI system introducing Automated Setup (physical AI for platform positioning), enhanced ScoPilot (intraoperative assistance), and Automated Operative Reports (via third-party AI integration), along with a 40% boot-time reduction and Mobile Standby Mode. A July 2025 FDA clearance added Wi-Fi/5G connectivity and a Predetermined Change Control Plan for ScoPilot, enabling cloud-to-edge AI feature deployment. A growing dataset of 3,000+ procedures (as of June 2026) powers the system's AI capabilities, supported by ISO 27001 and SOC 2 certifications for data security.

Moon Surgical employs a direct enterprise field sales model, supplemented by a mobile demo truck that brings hands-on Maestro demonstrations to hospitals. Pricing is not publicly disclosed but is structured as a multi-year contract that bundles the hardware, consumables, and ongoing software updates in a single cost - a transparent-pricing positioning relative to incumbents. As of December 2025, more than 2,300 patients had been treated across the US and Europe at named institutions including Lee Health's Gulf Coast Medical Center (Florida, 100+ procedures), Polyclinique de Franche-Comté (France), Arnault Tzanck Institute (France), CHU Saint-Pierre (Belgium, First-in-Human study), and Surgeon's Point Surgery Center (ASC setting). The company has raised approximately $86.7M+ across seed (2020, Sofinnova MD Start), Series A ($31.3M, May 2022, led by GT Healthcare Capital & Partners with Johnson & Johnson Innovation and Cathay Health), and Series B ($55.4M, May 2023, co-led by Sofinnova Partners and NVIDIA's NVentures).

Short descriptiontext

Moon Surgical is a Paris-based surgical robotics company developing the Maestro System, a collaborative robotic platform with AI capabilities for laparoscopic procedures. The company serves hospitals, surgical centers, and ambulatory surgery centers across the US and Europe, having treated more than 2,300 patients to date.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
surgical robotics platform, robotic-assisted laparoscopic surgery, AI-powered surgical assistance, minimally invasive surgery systems, collaborative robotic surgery
Industry3 codes
PRIMARYHLAHADAF
Surgical Robotics & Computer-Assisted Surgery Platforms
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAE
Operating Room Integration & Surgical Informatics (OR control, documentation, connectivity)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHDAAAIAC
Healthcare & Assistive Robotics
NAICS code2 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Surgical Appliance and Supplies Manufacturing339113
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Surgical Robotics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Maestro System (Robotic Hardware)
TypeHardware Sales
Description

Sale or placement of the Maestro surgical robotic system to hospitals and surgical centers. The system is designed for seamless integration into existing OR workflows.

moonsurgical.com
2Consumables and Instruments
TypeHardware Sales
Description

Revenue from compatible surgical instruments and consumables used with the Maestro system. The business model includes all consumables in one straightforward cost.

moonsurgical.com
3Software Updates and Upgrades
TypeSubscription Recurring
Description

Ongoing software updates and AI feature enhancements (e.g., ScoPilot, Maestro Insights) deployed across the installed base via cloud connectivity.

moonsurgical.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations, Infrastructure
Pricing details1 tier
1Maestro System - Commercial
ModelOtherBilling cadenceMulti-year contract
Notes

Pricing not publicly disclosed. The company notes a transparent business model covering consumables, resources, and software updates in one cost.

moonsurgical.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Maestro
Description

Surgical robotic assistance platform for laparoscopic surgery

moonsurgical.com
+3 more records
Core offering1 text field

Moon Surgical develops and sells the Maestro System, a collaborative and adaptive robotic surgical assistant platform that supports surgeons during laparoscopic and minimally invasive procedures. The system features gravity-defying arms compatible with off-the-shelf 5mm and 10mm instruments, requires no clutching or foot pedals, and offers same-day training with a 3-5 procedure learning curve. The company complements the hardware with AI-powered software features (ScoPilot, Maestro Insights) powered by NVIDIA Holoscan technology.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Over 2,300 patients treated across the US and Europe as of December 2025, with zero adverse events reported at Lee Health
+5 more records
Product overview1 text field

Moon Surgical offers the Maestro™ System as its core surgical robotics platform for laparoscopic procedures, accompanied by the Maestro Insights cloud analytics add-on module and the ScoPilot AI-powered laparoscope control feature. The Maestro platform provides a digitalized operating room with intelligent robotic arms that understand when to lock and unlock without clutching or foot pedals. The system integrates with standard 5mm and 10mm instruments. The product portfolio includes the cloud-based Maestro Insights platform for procedural analytics and administrative tools, and ScoPilot for AI-driven intraoperative assistance. The platform received initial FDA clearance in December 2022, commercial FDA clearance in June 2024, and CE Mark in September 2023, with Software Version 2.7 released in June 2026 adding multi-model Physical AI capabilities.

Product and service4 records
1Maestro System
CategorySurgical Robotics Hardware
Description

A surgical robotic assistance platform for laparoscopic and minimally invasive procedures that provides gravity-defying robotic arms for camera tracking and tissue exposure. Features same-day training, a 3-5 procedure learning curve, and compatibility with standard off-the-shelf 5mm and 10mm instruments. Requires no clutching or foot pedals. Available in US and EU markets following FDA clearance (December 2022, June 2024) and CE Mark (September 2023).

2Maestro Insights
CategoryCloud Analytics Software
Description

A cloud-based analytics platform that delivers procedural metrics, OR operational insights, and automated administrative tools for the Maestro System. Includes workflow optimization features for staff efficiency, continuous analysis for surgical quality enhancement, measured performance tracking, and cost control with transparent pricing. Powered by NVIDIA technology and enabled by edge-to-cloud connectivity across the installed base.

3ScoPilot
CategoryAI Surgical Assistance Software
Description

An AI-powered feature on the Maestro System that enables automatic laparoscope positioning during surgery using NVIDIA Holoscan technology. Provides real-time sensing, stable surgical visualization, and enhanced control by using the instruments being held to control the laparoscope, freeing the surgeon's hands while improving ergonomics.

4Maestro Software Version 2.7
CategorySoftware Platform Update
Description

A multi-model Physical AI platform update expanding the Maestro System from single AI capability to coordinated AI-driven features across the surgical workflow. Includes Automated Setup with physical AI positioning, enhanced ScoPilot intraoperative assistance with expanded clinical datasets, and Automated Operative Reports via third-party AI integration. Adds 40% boot time reduction and Mobile Standby Mode for rapid room-to-room transfer.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-03-23
Description

Strategic partnership announced March 2021 to develop machine learning for computer-assisted surgery. Combines academic research capabilities with Moon Surgical's robotic platform development.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Creator of the da Vinci surgical system, the dominant soft-tissue surgical robotics platform globally. Moon Surgical's board includes Intuitive's founder Fred Moll, and Maestro directly competes for the same laparoscopic soft-tissue procedures da Vinci has historically monopolized.

TypeBroad incumbent
Description

Developer of the Hugo robotic-assisted surgery system, a multi-port soft-tissue surgical robot. Hugo is one of the most credible competitive entrants to da Vinci and competes directly with Maestro in laparoscopic general surgery globally.

3Johnson & Johnson (Ottava)
TypeBroad incumbent
Description

J&J is developing the Ottava general surgery robotic platform while simultaneously being a strategic investor in Moon Surgical via J&J Innovation. Their potential entry is a competitive threat to Maestro and a sign of the incumbent's strategic interest in Moon Surgical's differentiated architecture.

TypeDirect peer
Description

UK-based developer of the Versius Surgical System, a modular, portable soft-tissue surgical robot designed for laparoscopic procedures. Versius targets the same value proposition of accessibility and lower total cost that Moon Surgical is pursuing with Maestro.

TypeEmerging player
Description

Developer of the Senhance surgical system, a digital laparoscopy platform with machine-vision and AI capabilities for soft-tissue surgery. Comparable as an emerging alternative in laparoscopic robotic surgery with a similar digital-surgery thesis.

TypeEmerging player
Description

Developer of a single-port robotic surgical system for abdominal procedures. Comparable as a venture-backed surgical robotics company targeting laparoscopic soft-tissue surgery with a differentiated human-like robotic architecture.

TypeEmerging player
Description

Developer of the Aquablation and HYDROS robotic systems for urology. Comparable as a venture-backed surgical robotics company that has scaled to commercialization and public markets, often cited as a peer for surgical robotics investors.

TypeBroad incumbent
Description

Stryker's Mako robotic system is the dominant orthopedic surgical robot. While Mako targets orthopedic procedures rather than soft-tissue laparoscopy, Stryker is a relevant broad incumbent demonstrating how an orthopedic-focused robot can scale into a multibillion-dollar franchise.

TypeEmerging player
Description

Developer of an AI-powered surgical visualization and intraoperative intelligence platform. Comparable as a surgical AI company with a focus on real-time intraoperative AI analogous to Moon Surgical's ScoPilot feature.

TypeEmerging player
Description

Developer of the Galaxy System, a robotic platform for navigated bronchoscopy. Comparable as a venture-backed robotic surgery company that has reached commercialization with FDA clearance, addressing a specific procedural niche.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability9 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles18 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Moon Surgical

Surgical Roboticsmoonsurgical.com

Moon Surgical is a Paris-based surgical robotics company developing the Maestro System, a collaborative robotic platform with AI capabilities for laparoscopic procedures. The company serves hospitals, surgical centers, and ambulatory surgery centers across the US and Europe, having treated more than 2,300 patients to date.

What Moon Surgical does

Moon Surgical is a Paris-based surgical robotics company, founded in 2020 (originally as MastOR), that develops the Maestro System, a collaborative and adaptive robotic platform designed to assist surgeons during laparoscopic and minimally invasive procedures. The system features gravity-defying robotic arms that operate without clutching or foot pedals, and is engineered to be compatible with standard off-the-shelf 5mm and 10mm instruments from any manufacturer - a deliberate departure from the proprietary-consumable model used by incumbent surgical robotics platforms. The Maestro platform is FDA-cleared (initial 510(k) in December 2022, commercial version in June 2024) and CE-marked (April 2023), and is sold to hospitals, surgical centers, and ambulatory surgery centers performing general, bariatric, gynecologic, and urologic procedures.

The platform's differentiation rests on integrated AI capabilities built on NVIDIA Holoscan technology. ScoPilot, FDA-cleared in March 2025, is the first AI application to run intraoperatively on any commercially available surgical robotic platform, providing automatic laparoscope positioning that frees the surgeon's hands. The platform evolved in June 2026 with Maestro Software Version 2.7 into a multi-model Physical AI system introducing Automated Setup (physical AI for platform positioning), enhanced ScoPilot (intraoperative assistance), and Automated Operative Reports (via third-party AI integration), along with a 40% boot-time reduction and Mobile Standby Mode. A July 2025 FDA clearance added Wi-Fi/5G connectivity and a Predetermined Change Control Plan for ScoPilot, enabling cloud-to-edge AI feature deployment. A growing dataset of 3,000+ procedures (as of June 2026) powers the system's AI capabilities, supported by ISO 27001 and SOC 2 certifications for data security.

Moon Surgical employs a direct enterprise field sales model, supplemented by a mobile demo truck that brings hands-on Maestro demonstrations to hospitals. Pricing is not publicly disclosed but is structured as a multi-year contract that bundles the hardware, consumables, and ongoing software updates in a single cost - a transparent-pricing positioning relative to incumbents. As of December 2025, more than 2,300 patients had been treated across the US and Europe at named institutions including Lee Health's Gulf Coast Medical Center (Florida, 100+ procedures), Polyclinique de Franche-Comté (France), Arnault Tzanck Institute (France), CHU Saint-Pierre (Belgium, First-in-Human study), and Surgeon's Point Surgery Center (ASC setting). The company has raised approximately $86.7M+ across seed (2020, Sofinnova MD Start), Series A ($31.3M, May 2022, led by GT Healthcare Capital & Partners with Johnson & Johnson Innovation and Cathay Health), and Series B ($55.4M, May 2023, co-led by Sofinnova Partners and NVIDIA's NVentures).

Moon Surgical firmographics

Firmographics
Name
Moon Surgical
Legal name
Moon Surgical
Website
https://moonsurgical.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
101–250 employees
Short description
Moon Surgical is a Paris-based surgical robotics company developing the Maestro System, a collaborative robotic platform with AI capabilities for laparoscopic procedures. The company serves hospitals, surgical centers, and ambulatory surgery centers across the US and Europe, having treated more than 2,300 patients to date.
Ownership category
akta.pro rank

Moon Surgical industry classification

Industry
Product category
Surgical Robotics
NAICS
Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHADAF
Surgical Robotics & Computer-Assisted Surgery Platforms
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHLAHADAE
Operating Room Integration & Surgical Informatics (OR control, documentation, connectivity)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Surgical Instruments, Endoscopy & OR Equipment
SECONDARYHDAAAIAC
Healthcare & Assistive Robotics

Keywords

  • Surgical robotics platform
  • Robotic-assisted laparoscopic surgery
  • AI-powered surgical assistance
  • Minimally invasive surgery systems
  • Collaborative robotic surgery

Where Moon Surgical is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices2 records

Markets served

Moon Surgical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations, Infrastructure

Revenue model

  1. Maestro System (Robotic Hardware): Sale or placement of the Maestro surgical robotic system to hospitals and surgical centers. The system is designed for seamless integration into existing OR workflows.
  2. Consumables and Instruments: Revenue from compatible surgical instruments and consumables used with the Maestro system. The business model includes all consumables in one straightforward cost.
  3. Software Updates and Upgrades: Ongoing software updates and AI feature enhancements (e.g., ScoPilot, Maestro Insights) deployed across the installed base via cloud connectivity.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractMaestro System - Commercial

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Moon Surgical product offering

Product offering

Core offering

Moon Surgical develops and sells the Maestro System, a collaborative and adaptive robotic surgical assistant platform that supports surgeons during laparoscopic and minimally invasive procedures. The system features gravity-defying arms compatible with off-the-shelf 5mm and 10mm instruments, requires no clutching or foot pedals, and offers same-day training with a 3-5 procedure learning curve. The company complements the hardware with AI-powered software features (ScoPilot, Maestro Insights) powered by NVIDIA Holoscan technology.

Product overview

Moon Surgical offers the Maestro™ System as its core surgical robotics platform for laparoscopic procedures, accompanied by the Maestro Insights cloud analytics add-on module and the ScoPilot AI-powered laparoscope control feature. The Maestro platform provides a digitalized operating room with intelligent robotic arms that understand when to lock and unlock without clutching or foot pedals. The system integrates with standard 5mm and 10mm instruments. The product portfolio includes the cloud-based Maestro Insights platform for procedural analytics and administrative tools, and ScoPilot for AI-driven intraoperative assistance. The platform received initial FDA clearance in December 2022, commercial FDA clearance in June 2024, and CE Mark in September 2023, with Software Version 2.7 released in June 2026 adding multi-model Physical AI capabilities.

Differentiator

Problem solved

Functional benefit

Brands

  • Maestro: Surgical robotic assistance platform for laparoscopic surgery
  • Maestro Insights
  • ScoPilot
  • Maestro System

Products and services

  • Maestro System A surgical robotic assistance platform for laparoscopic and minimally invasive procedures that provides gravity-defying robotic arms for camera tracking and tissue exposure. Features same-day training, a 3-5 procedure learning curve, and compatibility with standard off-the-shelf 5mm and 10mm instruments. Requires no clutching or foot pedals. Available in US and EU markets following FDA clearance (December 2022, June 2024) and CE Mark (September 2023).
  • Maestro Insights A cloud-based analytics platform that delivers procedural metrics, OR operational insights, and automated administrative tools for the Maestro System. Includes workflow optimization features for staff efficiency, continuous analysis for surgical quality enhancement, measured performance tracking, and cost control with transparent pricing. Powered by NVIDIA technology and enabled by edge-to-cloud connectivity across the installed base.
  • ScoPilot An AI-powered feature on the Maestro System that enables automatic laparoscope positioning during surgery using NVIDIA Holoscan technology. Provides real-time sensing, stable surgical visualization, and enhanced control by using the instruments being held to control the laparoscope, freeing the surgeon's hands while improving ergonomics.
  • Maestro Software Version 2.7 A multi-model Physical AI platform update expanding the Maestro System from single AI capability to coordinated AI-driven features across the surgical workflow. Includes Automated Setup with physical AI positioning, enhanced ScoPilot intraoperative assistance with expanded clinical datasets, and Automated Operative Reports via third-party AI integration. Adds 40% boot time reduction and Mobile Standby Mode for rapid room-to-room transfer.

Quantifiable outcome

  • Over 2,300 patients treated across the US and Europe as of December 2025, with zero adverse events reported at Lee Health
  • +5 more outcomes

Companies that use Moon Surgical

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Moon Surgical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability9 records

Feature6 records

Moon Surgical partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • King's College LondoncoreStrategic or Co-development Partner · 23 March 2021Strategic partnership announced March 2021 to develop machine learning for computer-assisted surgery. Combines academic research capabilities with Moon Surgical's robotic platform development.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Moon Surgical competitors and assessment

Company assessment

Direct peers

  • Intuitive Surgical: Creator of the da Vinci surgical system, the dominant soft-tissue surgical robotics platform globally. Moon Surgical's board includes Intuitive's founder Fred Moll, and Maestro directly competes for the same laparoscopic soft-tissue procedures da Vinci has historically monopolized.
  • CMR Surgical: UK-based developer of the Versius Surgical System, a modular, portable soft-tissue surgical robot designed for laparoscopic procedures. Versius targets the same value proposition of accessibility and lower total cost that Moon Surgical is pursuing with Maestro.

Broad incumbents

  • Medtronic: Developer of the Hugo robotic-assisted surgery system, a multi-port soft-tissue surgical robot. Hugo is one of the most credible competitive entrants to da Vinci and competes directly with Maestro in laparoscopic general surgery globally.
  • Johnson & Johnson (Ottava): J&J is developing the Ottava general surgery robotic platform while simultaneously being a strategic investor in Moon Surgical via J&J Innovation. Their potential entry is a competitive threat to Maestro and a sign of the incumbent's strategic interest in Moon Surgical's differentiated architecture.
  • Stryker (Mako): Stryker's Mako robotic system is the dominant orthopedic surgical robot. While Mako targets orthopedic procedures rather than soft-tissue laparoscopy, Stryker is a relevant broad incumbent demonstrating how an orthopedic-focused robot can scale into a multibillion-dollar franchise.

Emerging players

  • Asensus Surgical: Developer of the Senhance surgical system, a digital laparoscopy platform with machine-vision and AI capabilities for soft-tissue surgery. Comparable as an emerging alternative in laparoscopic robotic surgery with a similar digital-surgery thesis.
  • Vicarious Surgical: Developer of a single-port robotic surgical system for abdominal procedures. Comparable as a venture-backed surgical robotics company targeting laparoscopic soft-tissue surgery with a differentiated human-like robotic architecture.
  • PROCEPT BioRobotics: Developer of the Aquablation and HYDROS robotic systems for urology. Comparable as a venture-backed surgical robotics company that has scaled to commercialization and public markets, often cited as a peer for surgical robotics investors.
  • Activ Surgical: Developer of an AI-powered surgical visualization and intraoperative intelligence platform. Comparable as a surgical AI company with a focus on real-time intraoperative AI analogous to Moon Surgical's ScoPilot feature.
  • Noah Medical: Developer of the Galaxy System, a robotic platform for navigated bronchoscopy. Comparable as a venture-backed robotic surgery company that has reached commercialization with FDA clearance, addressing a specific procedural niche.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

Moon Surgical social profiles

Digital presence

Moon Surgical compliance and trust

Trust signal

Compliance4 records

Moon Surgical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Moon Surgical leadership team

Management profile

Number of profiles

Profiles18 records

Moon Surgical funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Moon Surgical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Moon Surgical

What does Moon Surgical do?

Moon Surgical develops and sells the Maestro System, a collaborative and adaptive robotic surgical assistant platform that supports surgeons during laparoscopic and minimally invasive procedures. The system features gravity-defying arms compatible with off-the-shelf 5mm and 10mm instruments, requires no clutching or foot pedals, and offers same-day training with a 3-5 procedure learning curve. The company complements the hardware with AI-powered software features (ScoPilot, Maestro Insights) powered by NVIDIA Holoscan technology.

Is Moon Surgical a public or private company?

Moon Surgical is a private company. It is classified as venture growth investor backed and is currently operating.

When was Moon Surgical founded?

Moon Surgical was founded in 2020. It employs 101 to 250 people.

Where is Moon Surgical based?

Moon Surgical is headquartered in Paris, France, in the Europe region.

How does Moon Surgical make money?

Three revenue lines are on record. Maestro System (Robotic Hardware) is the primary driver. The others are consumables and Instruments and software Updates and Upgrades.

Who are Moon Surgical's main competitors?

Direct peers on record are Intuitive Surgical and CMR Surgical. Broad incumbents are Medtronic, Johnson & Johnson (Ottava) and Stryker (Mako). Emerging players are Asensus Surgical, Vicarious Surgical, PROCEPT BioRobotics, Activ Surgical and Noah Medical.

Does Moon Surgical have an API?

No public API is recorded for Moon Surgical.

What industry is Moon Surgical in?

Moon Surgical's product category is Surgical Robotics. Its primary akta.pro industry code is HLAHADAF, Surgical Robotics & Computer-Assisted Surgery Platforms, with a secondary code of HLAHADAE, Operating Room Integration & Surgical Informatics (OR control, documentation, connectivity). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MassDeviceMoon Surgical, Karl Storz collab on surgical robotics, visualization techMoon Surgical and Karl Storz announced a new strategic commercial collaboration combining Moon's Maestro surgical robot platform with Karl Storz's 3D visualization and instrumentation for laparoscopic surgery. The partnership aims to create a more complete operating room ecosystem and expand access to minimally invasive surgical technology. The collaboration positions both companies to reach more surgeons and healthcare facilities, with Karl Storz pursuing this strategy after discontinuing its Asensus Surgical robotic business.MorningstarKARL STORZ Expands Its Robotics Ecosystem Through Strategic Partnerships in the USKARL STORZ announced US partnerships with Moon Surgical and Sovato to expand its robotic surgery ecosystem. The collaborations combine 3D visualization, robotic technologies, and operating room integration, initially available in the US before a global rollout. The partnerships aim to improve workflow efficiency and enable future connected surgical care.PR NewswireMoon Surgical and KARL STORZ Announce Strategic Commercial Collaboration to Advance Scalable SurgeryMoon Surgical and KARL STORZ announced a strategic commercial collaboration pairing Moon Surgical's Maestro platform with KARL STORZ 3D visualization and instrumentation. The partnership aims to expand access to advanced laparoscopic surgery and advance Scalable Surgery, making minimally invasive procedures more predictable and widely accessible.PR NewswireMoon Surgical and Uncovr Announce First 20 Clinical Cases of Automated Operative Reporting on Maestro®Moon Surgical and Uncovr announced the completion of the first 20 clinical cases using automated operative reporting on the Maestro® Platform, performed at Institut Arnaud Tzanck in Nice by three surgeons. This deployment represents the first third-party AI solution implemented on the Maestro platform in clinical practice, enabling AI-powered generation of operative reports from laparoscopic video within minutes of procedure completion. The companies view this milestone as validation of their open platform strategy and an early step toward broader commercial deployment of AI-enabled perioperative applications.AZoRoboticsMoon Surgical, SS Innovations International, and Microbot Medical Among Winners of the Surgical Robotics Industry Awards 2026Surgical Robotics Technology unveiled the winners of the Surgical Robotics Industry Awards 2026, selected through voting by the global surgical robotics community with over 50,000 votes cast. The awards recognized companies and individuals across six categories: Industry Leadership (Steve Bell), Innovative Start-up (Microbot Medical), Outstanding Company (SS Innovations International), Groundbreaking Technology (Sentante), Software Innovation (Maestro Insights by Moon Surgical), and Outstanding Healthcare Provider (Cohen Orthopedic). SS Innovations International also disclosed that its SSi Mantra Surgical Robotic System has surpassed 10,500 procedures globally and secured regulatory approvals in Colombia, Oman, Sri Lanka, and Kenya.MassDeviceMoon Surgical expands Maestro surgical robot into multi-model physical AI platformParis-based Moon Surgical announced Maestro Software Version 2.7, a platform update that expands its FDA-cleared surgical robotic assistant from a single AI capability to a multi-model intelligent platform. The update introduces three coordinated AI-driven features: automated setup with physical AI for platform positioning, enhanced ScoPilot for intraoperative assistance leveraging expanded clinical datasets, and automated operative reports via third-party AI integration. The company is deploying the new software across its installed base, with Version 2.7 representing the first integration of a third-party developed capability on the Maestro platform.AijournMoon Surgical Expands Maestro® Platform into a Multi-Model Physical AI Platform with Software Version 2.7, Driving Automation Across the Surgical WorkflowMoon Surgical announced Maestro® Software Version 2.7, a major platform update that transforms the system from a single AI capability into a multi-model intelligent platform operating across the surgical workflow, introducing three coordinated AI-driven capabilities for automated setup, intraoperative assistance, and post-operative documentation. The update includes a 40% boot time reduction, Mobile Standby Mode for rapid room-to-room transfer, and marks the first integration of a third-party developed application on the Maestro platform. The innovations are powered by Moon Surgical's growing dataset of over 3,000 procedures and are being deployed across the installed base.PR NewswireMoon Surgical Expands Maestro® Platform into a Multi-Model Physical AI Platform with Software Version 2.7, Driving Automation Across the Surgical WorkflowMoon Surgical announced Maestro® Software Version 2.7, a major platform update that expands the system from a single AI capability to a multi-model intelligent platform operating across the surgical workflow. The update introduces three AI-driven capabilities—Automated Setup (Physical AI), enhanced ScoPilot®, and Automated Operative Reports via third-party AI—while reducing boot time by 40% and marking the first third-party integration on the platform. The platform is powered by a dataset of over 3,000 procedures and is being deployed across the installed base, subject to regulatory requirements.PR NewswireMoon Surgical Expands Maestro® Platform into a Multi-Model Physical AI Platform with Software Version 2.7, Driving Automation Across the Surgical WorkflowMoon Surgical announced the release of Maestro Software Version 2.7, expanding its platform into a multi-model AI-enabled surgical workflow system. The update introduces new capabilities such as automated setup, enhanced intraoperative assistance, and automated operative reports, aiming to streamline surgical procedures and documentation.